XML 32 R16.htm IDEA: XBRL DOCUMENT v3.22.2
SHARE-BASED EMPLOYEE COMPENSATION
3 Months Ended
Jun. 30, 2022
Share-based Payment Arrangement [Abstract]  
SHARE-BASED EMPLOYEE COMPENSATION

(I) Share-BASED EMPLOYEE COMPENSATION

On August 7, 2013, our stockholders approved the Eagle Materials Inc. Amended and Restated Incentive Plan (the Plan), which increased the shares we are authorized to issue as awards by 3,000,000 (1,500,000 of which may be stock awards). Under the terms of the Plan, we can issue equity awards, including stock options, restricted stock units, restricted stock, and stock appreciation rights, to employees of the Company and members of the Board of Directors. The Compensation Committee of our Board of Directors specifies grant terms for awards under the Plan.

Long-Term Compensation Plans

OPTIONS

In May 2022, the Compensation Committee of the Board of Directors approved the granting to certain officers and key employees an aggregate of 25,192 performance-vesting stock options that will be earned only if certain performance conditions are satisfied (the Fiscal 2023 Employee Performance Stock Option Grant). The performance criteria for the Fiscal 2023 Employee Performance Stock Option Grant are based upon the achievement of certain levels of return on equity (as defined in the option agreements), ranging from 10.0% to 20.0%, for the fiscal year ending March 31, 2023. All stock options will be earned if the return on equity is 20.0% or greater, and the percentage of shares earned will be reduced proportionately to approximately 66.7% if the return on equity is 10.0%. If the Company does not achieve a return on equity of at least 10.0%, all granted stock options will be forfeited. Following any such reduction, restrictions on the earned stock options will lapse and the earned options will vest ratably over four years, with the initial fourth vesting promptly following the determination date, and the remaining options vesting on March 31, 2024 through 2026. The stock options have a term of 10 years from the grant date. The Compensation Committee also approved the granting of 20,994 time-vesting stock options to the same officers and key employees, which vest ratably over four years (the Fiscal 2023 Employee Time-Vesting Stock Option Grant).

 

The Fiscal 2023 Employee Performance Stock Option Grant and the Fiscal 2023 Employee Time-Vesting Stock Option Grant were valued at their grant date using the Black-Scholes option pricing model. The weighted-average assumptions used in the Black-Scholes model to value the option awards in fiscal 2023 are as follows:

 

 

 

 

Dividend Yield

 

 

0.8

%

Expected Volatility

 

 

38.2

%

Risk-Free Interest Rate

 

 

2.9

%

Expected Life

 

6.0 years

 

In addition to the stock options described above, from time to time we issue stock options to certain employees. Any options issued are valued using the Black-Scholes options pricing model on the grant date, and expensed over the vesting period.

Stock option expense for all outstanding stock option awards totaled approximately $0.8 million and $0.7 million for the three months ended June 30, 2022 and 2021, respectively. At June 30, 2022, there was approximately $5.7 million of unrecognized compensation cost related to outstanding stock options, which is expected to be recognized over a weighted-average period of 2.5 years.

The following table represents stock option activity for the three months ended June 30, 2022:

 

 

 

Number
of Shares

 

 

Weighted-
Average
Exercise
Price

 

Outstanding Options at March 31, 2022

 

 

456,849

 

 

$

83.81

 

Granted

 

 

51,522

 

 

$

125.88

 

Exercised

 

 

(17,159

)

 

$

125.12

 

Cancelled

 

 

 

 

$

 

Outstanding Options at June 30, 2022

 

 

491,212

 

 

$

88.85

 

Options Exercisable at June 30, 2022

 

 

298,520

 

 

 

 

Weighted-Average Fair Value of Options Granted
During the Year

 

$

125.88

 

 

 

 

The following table summarizes information about stock options outstanding at June 30, 2022:

 

 

 

Options Outstanding

 

 

Options Exercisable

 

Range of Exercise Prices

 

Number of
Shares
Outstanding

 

 

Weighted-
Average
Remaining
Contractual
Life (in years)

 

 

Weighted-
Average
Exercise
Price

 

 

Number of
Shares
Outstanding

 

 

Weighted-
Average
Exercise
Price

 

$59.32 - $81.56

 

 

172,395

 

 

 

7.08

 

 

$

62.87

 

 

 

85,585

 

 

$

64.96

 

$87.37 - $93.03

 

 

151,569

 

 

 

6.58

 

 

$

91.57

 

 

 

109,241

 

 

$

91.57

 

$99.37 - $143.09

 

 

167,248

 

 

 

7.18

 

 

$

113.16

 

 

 

103,694

 

 

$

106.15

 

 

 

 

491,212

 

 

 

6.96

 

 

$

88.85

 

 

 

298,520

 

 

$

89.00

 

 

At June 30, 2022, the aggregate intrinsic value for both the outstanding and exercisable options was approximately $10.4 million and $6.3 million, respectively. The total intrinsic value of options exercised during the three months ended June 30, 2022 was approximately $1.0 million.

RESTRICTED STOCK

In May 2022, the Compensation Committee approved the granting to certain officers and key employees an aggregate of 50,783 shares of performance-vesting restricted stock that will be earned if certain performance conditions are satisfied (the Fiscal 2023 Employee Restricted Stock Performance Award). The performance criteria for the Fiscal 2023 Employee Restricted Stock Performance Award are based upon the achievement of certain levels of return on equity (as defined in the award agreement), ranging from 10.0% to 20.0%, for the fiscal

year ending March 31, 2023. All restricted shares will be earned if the return on equity is 20.0% or greater, and the percentage of shares earned will be reduced proportionately to approximately 66.7% if the return on equity is 10.0%. If the Company does not achieve a return on equity of at least 10.0%, all awards will be forfeited. Following any such reduction, restrictions on the earned shares will lapse ratably over four years, with the initial fourth lapsing promptly following the determination date, and the remaining restrictions lapsing on March 31, 2024 through 2026. The Compensation Committee also approved the granting of 42,545 shares of time-vesting restricted stock to the same officers and key employees, which vest ratably over four years (the Fiscal 2023 Employee Restricted Stock Time-Vesting Award). The Fiscal 2023 Employee Restricted Stock Performance Award and the Fiscal 2023 Employee Restricted Stock Time-Vesting Award were valued at the closing price of the stock on the grant date and are being expensed over a four-year period.

In addition to the restricted stock described above, from time to time we issue restricted stock to certain employees. These awards are valued at the closing price of the stock on the grant date, and expensed over the vesting period.

The fair value of restricted stock is based on the stock price on the grant date. The following table summarizes the activity for nonvested restricted shares during the three months ended June 30, 2022:

 

 

 

Number of Shares

 

 

Weighted-Average Grant Date Fair Value

 

Nonvested Restricted Stock at March 31, 2022

 

 

258,779

 

 

$

85.34

 

Granted

 

 

96,135

 

 

$

126.01

 

Vested

 

 

(28,746

)

 

$

133.85

 

Forfeited

 

 

 

 

$

 

Nonvested Restricted Stock at June 30, 2022

 

 

326,168

 

 

$

94.66

 

Expense related to restricted shares was approximately $4.3 million and $1.8 million for the three months ended June 30, 2022, and 2021, respectively. At June 30, 2022, there was approximately $25.6 million of unearned compensation from restricted stock, which will be recognized over a weighted-average period of 2.7 years.

The number of shares available for future grants of stock options, restricted stock units, stock appreciation rights, and restricted stock under the Plan was 3,271,524 at June 30, 2022.